Prostacyclin in Prostatic Cancer: A Better Marker than Bone Scan or Serum Acid Phosphatase?

Publisher Website
Google Scholar
Abstract
Prostaglandins have been implicated in the development and spread of malignant tumors. Gas chromatography and mass spectrometry (GC-MS) analysis of prostaglandins in benign and malignant prostatic tissue showed that prostacyclin (PGI2), a prostanoid known to induce bone resorption, was the major component. PGI2 is hydrolyzed to 6-oxo-PGF1.alpha.. Plasma levels of 6-oxo-PFG1.alpha. were measured as an index of PGI2 formation in patients with benign and malignant prostatic disease. The mean plasma 6-oxo- level in an age-matched control group was comparable to that of patients with benign prostatic hypertrophy. A significant elevation was found in patients with a TO carcinoma (P < 0.05). Plasma 6-oxo- levels rise with advancing disease and the concentration varied with the degree of tumor differentiation. Plasma 6-oxo- levels were a more accurate monitor of disease progression than tartrate labile acid phosphatase in patients with M1 carcinoma. Persistently elevated levels were associated with a bad prognosis.